Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)

Michael Pratta, Angelina Volkova, Maureen Bleam, Rodica Morariu-Zamfir, Beth Rumberger, Stephen Douglass, Susan H. Smith, Valkal Bhatt, John Galvin, Annie Im, Sophie Paczesny, Kirk R. Schultz, Steven Z. Pavletic

Blood (2023) 142 (Supplement 1): 2197.

https://doi.org/10.1182/blood-2023-174955

Published: 2023

Journal Articles

Trial in Progress: Patient-Reported Outcome Measures in the Prospective Observational Cohort Study of Patients at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Doris M. Ponce, Areej El-Jawahri, Betty K. Hamilton, Nandita Khera, Valkal Bhatt, John Galvin, Catherine J. Lee

Blood (2023) 142 (Supplement 1): 7035.

https://doi.org/10.1182/blood-2023-178073

Published: 2023

Journal Articles

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized, Phase 3 REACH3 Study

Robert Zeiser, Zhenyi Xue, Valkal Bhatt, John Galvin, Franco Locatelli

Blood (2022) 140 (Supplement 1): 10507–10508.

https://doi.org/10.1182/blood-2022-170186

Published: 2022

Journal Articles

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Aaron T. Gerds, Michael R. Grunwald, Stephen T. Oh, Evan Braunstein, Zhenyi Xue, Valkal Bhatt, Jingbo Yu, Ruben Mesa

Blood (2022) 140 (Supplement 1): 6810–6812.

https://doi.org/10.1182/blood-2022-158144

Published: 2022

Journal Articles

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study

Gérard Socié, Zhenyi Xue, Valkal Bhatt, John Galvin, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 4765–4766.

https://doi.org/10.1182/blood-2022-169717

Published: 2022

Journal Articles

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Stephanie Lee, Franco Locatelli, Francis A. Ayuk, Tsila Zuckerman, Kentaro Fukushima, Juan Carlos Vallejo Llamas, Joseph Pidala, Nada Hamad, Ivan S. Moiseev, Francesca Bonifazi, Shashikant Apte, Robert Zeiser, Valkal Bhatt, Maanasa Gowda, Jackie Han, Tommaso Stefanelli, Mike W. Zuurman, Takanori Teshima

Blood (2021) 138 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2021-144576

Published: 2021

Journal Articles

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Parameswaran Hari, MD MRCP, Haris Ali, MD, Yi-Bin Chen, MD, Salman Fazal, MD, Tara K. Gregory, MD, Sarah M. Anand, MD, Ahmad Naim, MD, Dilan Paranagama, PhD, Valkal Bhatt, PharmD, Amy Blithe, RD, John F. DiPersio, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140541

Published: 2020

Journal Articles

Outpatient BEAM Using Daily Etoposide and Cytarabine with Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Is Feasible and Decreases Inpatient Length of Stay

Blood (2019) 134 (Supplement_1): 5830.

https://doi.org/10.1182/blood-2019-127402

Published: 2019

Journal Articles

Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on Close Haplo-Winning CB Unit HLA-Match

Blood (2018) 132 (Supplement 1): 2078.

https://doi.org/10.1182/blood-2018-99-116276

Published: 2018

Journal Articles

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

Gunjan L. Shah, MD, Andrew Lin, PharmD, Ryan Schofield, MS, Caitlin Sarubbi, AB, Elaina V. Preston, PA-C,MPH, Sean M. Devlin, PhD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Elizabeth Hoover, BS, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD, Heather Landau, MD

Blood (2017) 130 (Supplement 1): 2023.

https://doi.org/10.1182/blood.V130.Suppl_1.2023.2023

Published: 2017

Journal Articles

More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

Jeremy Pappacena, PharmD, Valkal Bhatt, PharmD, BCOP, BCPS, Gunjan L. Shah, MD, Patrick Hilden, MS, Molly Maloy, MS, Larry W Buie, PharmD, BCOP, FASHP, Sergio A. Giralt, MD, Michael Scordo, MD

Blood (2017) 130 (Supplement 1): 1950.

https://doi.org/10.1182/blood.V130.Suppl_1.1950.1950

Published: 2017

Journal Articles

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

Gunjan L. Shah, MD, Heather Landau, MD, Caitlin Sarubbi, A.B, Ryan Schofield, MS, Andrew Lin, PharmD, Valkal Bhatt, PharmD, Stephen J. Harnicar, PharmD, Sean M. Devlin, PhD, David J. Chung, MDPhD, Parastoo B. Dahi, MD, Guenther Koehne, MDPhD, Roni Tamari, MD, Dean Carlow, MDPhD, Sergio A. Giralt, MD

Blood (2017) 130 (Supplement 1): 3296.

https://doi.org/10.1182/blood.V130.Suppl_1.3296.3296

Published: 2017

Journal Articles

Outcomes of Pharmacokinetically Targeted Busulfan-Based Conditioning Regimen for Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia Undergoing CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation

Kristen Beyer, PharmD, Anthony Proli, PharmD, Junting Zheng, Sean Devlin, PhD, Valkal Bhatt, PharmD, Andrew Lin, PharmD, Esperanza B. Papadopoulos, MD, Ann A. Jakubowski, MD PhD, Miguel Perales, MD, Sergio Giralt, MD, Hugo Castro-Malaspina, MD, Roni Tamari, MD

Blood (2016) 128 (22): 3392.

https://doi.org/10.1182/blood.V128.22.3392.3392

Published: 2016

Journal Articles

Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients

Carmen Lau, PharmD, Valkal Bhatt, PharmD, Parastoo B. Dahi, MD, Sean Devlin, PhD, Yeon Yoo, BS, Nelly G. Adel, PharmD, BCOP, BCPS, Chris Mazis, Miguel Perales, MD, Sergio A. Giralt, MD, Guenther Koehne, MD PhD, Doris M Ponce, MD, Genovefa A Papanicolaou, MD, Juliet N. Barker, MBBS (Hons)

Blood (2016) 128 (22): 2219.

https://doi.org/10.1182/blood.V128.22.2219.2219

Published: 2016

Journal Articles

A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning

Michael Scordo, MD, Valkal Bhatt, PharmD, Meier Hsu, MS, Antonio M. Omuro, MD, Matthew J. Matasar, MD MS, Lisa DeAngelis, MD, Parastoo B. Dahi, MD, Craig H. Moskowitz, MD, Sergio A. Giralt, MD, Craig S. Sauter, MD

Blood (2015) 126 (23): 4354.

https://doi.org/10.1182/blood.V126.23.4354.4354

Published: 2015

Journal Articles

Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) in Adult Allogeneic Stem Cell Transplant (HSCT) Recipients

Blood (2015) 126 (23): 4332.

https://doi.org/10.1182/blood.V126.23.4332.4332

Published: 2015

Journal Articles

Outcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS Lymphoma

Valkal Bhatt, PharmD, Michael Scordo, MD, Meier Hsu, MS, Antonio M. Omuro, MD, Lisa DeAngelis, MD, Andrew Lin, PharmD, Matthew J. Matasar, MD MS, Parastoo B. Dahi, MD, Craig H. Moskowitz, MD, Sergio A. Giralt, MD, Craig S. Sauter, MD

Blood (2015) 126 (23): 1994.

https://doi.org/10.1182/blood.V126.23.1994.1994

Published: 2015

Journal Articles

Autoimmune Hemolysis & Immune Thrombocytopenic Purpura after Cord Blood Transplantation (CBT) May be Life-Threatening & Warrants Early Therapy with Rituximab

Valkal Bhatt, PharmD, Leyla Shune, MD, Emily J Lauer, BS, BA, Marissa N Lubin, BA, Sean M. Devlin, PhD, Andromachi Scaradavou, MD, Nancy A. Kernan, MD, Sergio Giralt, MD, Rekha Parameswaran, MD, Miguel-Angel Perales, MD, Doris M. Ponce, MD, Gerald A. Soff, MD, Juliet N. Barker, MBBS(Hons), FRACP

Blood (2014) 124 (21): 1142.

https://doi.org/10.1182/blood.V124.21.1142.1142

Published: 2014

Journal Articles

Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience

Matthew Alexander Lunning, DO, Erika Pamer, BA, Lauren Wintman, BS, Valkal Bhatt, PharmD, Joachim Yahalom, MD, Alison J. Moskowitz, MD, Jenna D Goldberg, MD, David J. Straus, MD, Paul Hamlin, MD, Andrew D Zelenetz, MD, PhD, Steven M. Horwitz, MD

Blood (2011) 118 (21): 2688.

https://doi.org/10.1182/blood.V118.21.2688.2688

Published: 2011

NARROW

Janus Kinase (JAK) 1 Inhibition Results in Significant Changes in Serum Proteins and Peripheral T-Cell Populations That Correlated with Clinical Scores in Chronic Graft Versus Host Disease (GVHD) Patients (an Analysis from GRAVITAS-309)

Trial in Progress: Patient-Reported Outcome Measures in the Prospective Observational Cohort Study of Patients at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized, Phase 3 REACH3 Study

Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL

Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

Outpatient BEAM Using Daily Etoposide and Cytarabine with Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Is Feasible and Decreases Inpatient Length of Stay

Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on Close Haplo-Winning CB Unit HLA-Match

Feasibility, Tolerability, and Patient-Reported Outcomes with Pharmacokinetic (PK)-Directed Dosing of Evomela® (propylene glycol free melphalan) for Multiple Myeloma and AL Amyloidosis Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT)

More Intensive Fludarabine/Busulfan (Flu/Bu) Conditioning Regimens Result in Similar Outcomes without Adding Serious Toxicity When Compared to Fludarabine/Melphalan (Flu/Mel) in Patients Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT)

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

Outcomes of Pharmacokinetically Targeted Busulfan-Based Conditioning Regimen for Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia Undergoing CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation

Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients

A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning

Low Dose Unfractionated Heparin (UFH) Prophylaxis Is a Safe Strategy for the Prevention of Hepatic Sinusoidal Obstruction Syndrome (SOS) in Adult Allogeneic Stem Cell Transplant (HSCT) Recipients

Outcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS Lymphoma

Autoimmune Hemolysis & Immune Thrombocytopenic Purpura after Cord Blood Transplantation (CBT) May be Life-Threatening & Warrants Early Therapy with Rituximab

Modified SMILE in the Treatment of Natural Killer T-Cell Lymphoma, Nasal and Nasal Type: A Single Center US Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only